PHARMACY

Sanofi, Merck get Vaxelis approval

BY DSN STAFF

Sanofi and Merck have received the Food and Drug Administration’s blessing for Vaxelis (diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus, haemophilus b conjugate [Meningococcal Protein Conjugate] and Hepatitis B [Recombinant] Vaccine) for use in children from 6 weeks through 4 years of age, or prior to the 5th birthday.

Vaxelis was developed as part of a joint partnership between Sanofi and Merck.

Commercial supply will not be available in the United States prior to 2020.

Vaxelils is approved for use as a 3-dose series in children 6 weeks through 4 years of age (prior to the 5th birthday).

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

What area is your company focused most on in 2019?
  • Add your answer